Epidermal growth factor receptor (EGFR) -tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of patients with EGFR-mutant non-small cell lung cancer (NSCLC). Here, EGFR is linked to non-small cell lung carcinoma.